Heidi D Klepin1, Janet A Tooze2, Timothy S Pardee3, Leslie R Ellis3, Dmitriy Berenzon3, Shannon L Mihalko4, Suzanne C Danhauer2, Arati V Rao5, Tanya M Wildes6, Jeff D Williamson7, Bayard L Powell3, Stephen B Kritchevsky7. 1. Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina. hklepin@wakehealth.edu. 2. Division of Public Health Sciences, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, North Carolina. 3. Wake Forest Baptist Comprehensive Cancer Center, Wake Forest University, Winston-Salem, North Carolina. 4. Wake Forest University Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina. 5. Duke University School of Medicine, Durham, North Carolina. 6. Washington University School of Medicine, St. Louis, Missouri. 7. Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Abstract
OBJECTIVES: To measure short-term changes in physical and cognitive function and emotional well-being of older adults receiving intensive chemotherapy for acute myeloid leukemia (AML). DESIGN: Prospective observational study. SETTING: Single academic institution. PARTICIPANTS: Individuals aged 60 and older with newly diagnosed AML who received induction chemotherapy (N = 49, mean age 70 ± 6.2, 56% male). MEASUREMENTS: Geriatric assessment (GA) was performed during inpatient examination for AML and within 8 weeks after hospital discharge after induction chemotherapy. Measures were the Pepper Assessment Tool for Disability (activity of daily living, instrumental activity of daily living (IADL), mobility questions), Short Physical Performance Battery (SPPB), grip strength, Modified Mini-Mental State examination, Center for Epidemiologic Studies Depression Scale, and the Distress Thermometer. Changes in GA measures were assessed using paired t-tests. Analysis of variance models were used to evaluate relationships between GA variables and change in function over time. RESULTS: After chemotherapy, IADL dependence worsened (mean 1.4 baseline vs 2.1 follow-up, P < .001), as did mean SPPB scores (7.5 vs 5.9, P = .02 for total). Grip strength also declined (38.9 ± 7.7 vs 34.2 ± 10.3 kg, P < .001 for men; 24.5 ± 4.8 vs 21.8 ± 4.7 kg, P = .007 for women). No significant changes in cognitive function (mean 84.7 vs 85.1, P = .72) or depressive symptoms (14.0 vs. 11.3, P = .11) were detected, but symptoms of distress declined (5.0 vs 3.2, P < .001). Participants with depressive symptoms at baseline and follow-up had greater declines in SPPB scores those without at both time points. CONCLUSIONS: Short-term survivors of intensive chemotherapy for AML had clinically meaningful declines in physical function. These data support the importance of interventions to maintain physical function during and after chemotherapy. Depressive symptoms before and during chemotherapy may be linked to potentially modifiable physical function declines.
OBJECTIVES: To measure short-term changes in physical and cognitive function and emotional well-being of older adults receiving intensive chemotherapy for acute myeloid leukemia (AML). DESIGN: Prospective observational study. SETTING: Single academic institution. PARTICIPANTS: Individuals aged 60 and older with newly diagnosed AML who received induction chemotherapy (N = 49, mean age 70 ± 6.2, 56% male). MEASUREMENTS: Geriatric assessment (GA) was performed during inpatient examination for AML and within 8 weeks after hospital discharge after induction chemotherapy. Measures were the Pepper Assessment Tool for Disability (activity of daily living, instrumental activity of daily living (IADL), mobility questions), Short Physical Performance Battery (SPPB), grip strength, Modified Mini-Mental State examination, Center for Epidemiologic Studies Depression Scale, and the Distress Thermometer. Changes in GA measures were assessed using paired t-tests. Analysis of variance models were used to evaluate relationships between GA variables and change in function over time. RESULTS: After chemotherapy, IADL dependence worsened (mean 1.4 baseline vs 2.1 follow-up, P < .001), as did mean SPPB scores (7.5 vs 5.9, P = .02 for total). Grip strength also declined (38.9 ± 7.7 vs 34.2 ± 10.3 kg, P < .001 for men; 24.5 ± 4.8 vs 21.8 ± 4.7 kg, P = .007 for women). No significant changes in cognitive function (mean 84.7 vs 85.1, P = .72) or depressive symptoms (14.0 vs. 11.3, P = .11) were detected, but symptoms of distress declined (5.0 vs 3.2, P < .001). Participants with depressive symptoms at baseline and follow-up had greater declines in SPPB scores those without at both time points. CONCLUSIONS: Short-term survivors of intensive chemotherapy for AML had clinically meaningful declines in physical function. These data support the importance of interventions to maintain physical function during and after chemotherapy. Depressive symptoms before and during chemotherapy may be linked to potentially modifiable physical function declines.
Authors: H Mohamedali; H Breunis; N Timilshina; J M Brandwein; V Gupta; M D Minden; M Li; G Tomlinson; R Buckstein; S M H Alibhai Journal: Leuk Res Date: 2012-06-21 Impact factor: 3.156
Authors: Arti Hurria; Kayo Togawa; Supriya G Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Stuart M Lichtman; Ajeet Gajra; Smita Bhatia; Vani Katheria; Shira Klapper; Kurt Hansen; Rupal Ramani; Mark Lachs; F Lennie Wong; William P Tew Journal: J Clin Oncol Date: 2011-08-01 Impact factor: 44.544
Authors: Christian J Nelson; Christina Cho; Alexandra R Berk; Jimmie Holland; Andrew J Roth Journal: J Clin Oncol Date: 2009-12-07 Impact factor: 44.544
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: Shabbir M H Alibhai; Marc Leach; Vikas Gupta; George A Tomlinson; Joseph M Brandwein; Fernando Suarez Saiz; Mark D Minden Journal: Crit Rev Oncol Hematol Date: 2008-09-07 Impact factor: 6.312
Authors: Shabbir M H Alibhai; Sara O'Neill; Karla Fisher-Schlombs; Henriette Breunis; Narhari Timilshina; Joseph M Brandwein; Mark D Minden; George A Tomlinson; S Nicole Culos-Reed Journal: Support Care Cancer Date: 2013-11-16 Impact factor: 3.603
Authors: Nikesha Gilmore; Lee Kehoe; Jessica Bauer; Huiwen Xu; Bianca Hall; Megan Wells; Lianlian Lei; Eva Culakova; Marie Flannery; Valerie Aarne Grossman; Ronak Amir Sardari; Himal Subramanya; Sindhuja Kadambi; Elizabeth Belcher; Jared Kettinger; Mark A O'Rourke; Elie G Dib; Nicholas J Vogelzang; William Dale; Supriya Mohile Journal: Oncologist Date: 2021-09-19
Authors: Arti Hurria; Enrique Soto-Perez-de-Celis; Jacob B Allred; Harvey Jay Cohen; Anait Arsenyan; Karla Ballman; Jennifer Le-Rademacher; Aminah Jatoi; Julie Filo; Jeanne Mandelblatt; Jacqueline M Lafky; Gretchen Kimmick; Heidi D Klepin; Rachel A Freedman; Harold Burstein; Julie Gralow; Antonio C Wolff; Gustav Magrinat; Myra Barginear; Hyman Muss Journal: J Am Geriatr Soc Date: 2018-08-26 Impact factor: 5.562
Authors: Heidi D Klepin; Ellen Ritchie; Brittny Major-Elechi; Jennifer Le-Rademacher; Drew Seisler; Libby Storrick; Ben L Sanford; Guido Marcucci; Weiqiang Zhao; Susan A Geyer; Karla V Ballman; Bayard L Powell; Maria R Baer; Wendy Stock; Harvey Jay Cohen; Richard M Stone; Richard A Larson; Geoffrey L Uy Journal: J Geriatr Oncol Date: 2019-10-24 Impact factor: 3.599
Authors: Kah Poh Loh; Janet A Tooze; Barbara J Nicklas; Stephen B Kritchevsky; Jeff D Williamson; Leslie R Ellis; Bayard L Powell; Timothy S Pardee; Neha G Goyal; Heidi D Klepin Journal: J Geriatr Oncol Date: 2019-04-05 Impact factor: 3.599